1. A compound of formula (I) or any of its pharmaceutically acceptable soleyv wherein: R is an aromatic ring which is not substituted or substituted by one or more atoms or groups of atoms selected from the group halogen, C-alkyl group,, C-Salkoksigrupp, nitro- , cyano, trifluoromethyl or trifluoromethoxy, R represents a hydrogen atom or a linear, branched or cyclic hydrocarbon chain having from 1 to 4 carbon atoms, an optionally substituted phenyl group, CONHgruppoy or one or more atom ohms fluorine atom R represents a hydrogen atom, a hydroxyl group or forms with R-CH = N- group or a linear or branched C Salkilenovuyu group R represents a hydrogen atom or forms with R-CH = N-group or a linear or branched C Salkilenovuyu group R represents a hydrogen atom or C-alkyl group,, R is hydrogen or halogen Y is C-Salkilenovuyu group zameschennuyuili unsubstituted, linear or branched, optionally containing an oxygen atom between two carbon atoms, to pr prophylaxis, therapy and / or reduce edema makuly.2. Use of a compound according to Claim. 1 to prevent, treat and / or reduce macular edema, characterized in that said macular edema is caused by or associated with diabetic retinopatiey.3. Use of compounds according to claim 1 for the prevention, treatment and / or reduce macular edema, characterized in that the compound is №. 49: or any of its pharmaceutically acceptable soley.4. Use according to claim. 1 to prevent, treat and / or reduce macular edema according to Claim. 1, wherein the pharmaceutically acceptable salt thereof1. Применение соединения формулы (I) или любого из его фармацевтически приемлемых солейв которой:R1 представляет собой ароматическое кольцо, не замещенное или замещенное одним или более атомами или группами атомов, выбранными из групп галогена, C1-С3 алкильных групп, C1-С3 алкоксигрупп, нитро-, циано-, трифторметил- или трифторметоксигруппR2 представляет собой атом водорода или линейную, разветвленную или циклическую углеводородную цепь, содержащую от 1
